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This paper discusses the current status of imaging in the investigation of patients with haematuria. The physician must rationalize
imaging so that serious causes such as malignancy are promptly diagnosed while at the same time not exposing patients
to unnecessary investigations. There is currently no universal agreement about the optimal imaging work up of haematuria.
The choice of modality to image the urinary tract will depend on individual patient factors such as age, the presence of risk
factors for malignancy, renal function, a history of calculus disease and pregnancy, and other factors, such as local policy
and practice, cost effectiveness and availability of resources. The role of all modalities, including conventional radiography,
intravenous urography/excretory urography, ultrasonography, retrograde pyelography, multidetector computed tomography
urography (MDCTU), and magnetic resonance urography, is discussed. This paper highlights the pivotal role of MDCTU in the
imaging of the patient with haematuria and discusses issues specific to this modality including protocol design, imaging of the
urothelium, and radiation dose. Examination protocols should be tailored to the patient while all the while optimizing radiation
dose.
1. Introduction
Haematuria can be microscopic or macroscopic (visible to
the naked eye) in nature, but both forms may be the sole
manifestation of underlying serious pathology. Haematuria is
most accurately defined as the presence of three or more red
blood cells per high-powered field in two of three properly
collected urinalysis specimens [1, 2]. It may be symptomatic
or asymptomatic and occur in isolation or in association with
other urinary tract abnormalities [3].
The more common causes of haematuria include urinary
tract infection, urolithiasis, trauma, renal parenchymal dis-
ease, and malignancy [4]. The most common primary malig-
nancies associated with haematuria are renal cell carcinoma,
urothelial cell carcinoma, prostate carcinoma, and, less com-
monly, squamous cell carcinoma [5]. Renal cell carcinoma
accounts for 92% of all renal neoplasms with urothelial car-
cinoma representing 7% of upper urinary tract malignancies
[6].Themajority of urothelial lesions occur in the bladder but
synchronous lesions occur in 2% of renal urothelial lesions
and 9% of ureteric lesions [7]. Due to the multifocal nature
of urothelial carcinoma, an evaluation of the urothelium,
including thorough evaluation of the upper urinary tracts, is
warranted and represents a significant diagnostic challenge
to the clinician. This paper discusses the current status of
imaging in patients suspected of having a urological cause
of haematuria. The evaluation of patients presenting with
haematuria in the context of trauma, glomerular disease, and
infection is beyond the scope of this review.
The role of all modalities, including conventional radio-
graphy, intravenous urography (IVU)/excretory urogra-
phy, ultrasonography, retrograde pyelography, multidetector
computed tomography urography (MDCTU), and magnetic
resonance urography (MRU), is discussed. This paper high-
lights the pivotal role ofMDCTU in the imaging of the patient
with haematuria and discusses issues specific to this modality
including protocol design, imaging of the urothelium, and
radiation dose.
2. Investigation of Haematuria
The initial decision is to determine if all patients presenting
with haematuria require imaging evaluation. The evaluation
of haematuria should begin with a search for potential benign
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causes including menstruation, vigorous exercise, sexual
activity, and infection [1]. In the absence of infection, the
next step is to distinguish glomerular and nonglomerular
causes of haematuria. The presence of proteinuria, red cell
casts, dysmorphic red blood cells, or an elevated creatinine
suggests a glomerular cause [1]. If the findings suggest a
glomerular source of bleeding, urological referral is not
required initially and referral to a nephrologist for further
management is warranted [1, 8]. If a glomerular source
is excluded, urological referral is indicated. The choice to
investigate asymptomatic microscopic haematuria remains
controversial. The prevalence of asymptomatic microscopic
haematuria in the general population has been reported
as varying between 0.2% and 21% [9]. Patients without a
discernable urinary tract abnormality may normally release
small amounts of red blood cells into urine so that one or two
red blood cells may be visible at microscopy. Furthermore,
microscopic haematuria can be intermittent, even in patients
in which a malignancy is subsequently detected [10]. The
low prevalence of significant urological malignancy in young
patients with asymptomatic microscopic haematuria has led
many authors to suggest that no imaging evaluation is
necessary in this subgroup [11].
Macroscopic haematuria conveys a much higher risk
of malignancy and warrants prompt investigation in all
cases [12]. Urinary tract malignancy is four times more
common in patients with macroscopic haematuria than
microscopic haematuria with gross haematuria being the
presenting symptom in 80% of bladder cancers and half of
all renal cancers [13]. The prevalence of malignancy was
10% and 34.5% amongst patients under and over 50 years
of age, respectively, in one series [14]. Therefore patients
with macroscopic haematuria require complete evaluation of
the upper and lower urinary tracts with upper urinary tract
imaging and cystoscopy to exclude neoplasia.
Risk factors for urinary tract malignancy include smok-
ing, occupational exposure to benzenes or aromatic amines,
recurrent urinary tract infections, a history of irritative void-
ing symptoms, cyclophosphamide intake, pelvic irradiation,
and analgesic abuse [1].
According to the British Association of Urological Sur-
geons, patients with macroscopic haematuria, symptomatic
microscopic haematuria, and those over 40 years of age or
with other risk factors with asymptomatic microscopic hae-
maturia should be referred for urological investigation [15].
Haematuria in patients receiving oral antiplatelet agents
or anticoagulants is often attributed to excessive anticoag-
ulation. However, an underlying malignancy was found in
24% and 7% of patients in two separate series and thorough
urological evaluation should not be foregone in patients
receiving anticoagulants [16, 17].
The physician must rationalize the investigation of
haematuria so that serious causes such as malignancy are
promptly diagnosed while at the same time not exposing
patients to unnecessary investigations with the potential for
adverse events and unwanted consequences such as anxiety
and radiation dose.
Complete urological evaluation for haematuria includes
a full history and physical examination, laboratory analysis,
and radiological imaging of the upper urinary tract followed
by cystoscopic examination of the urinary bladder [1]. Uri-
nary cytology, although controversial, often constitutes part
of the initial work up for hematuria [18]. However, it has a
high false negative rate for the detection of malignancy with
a reported sensitivity of only 25% [19].
Furthermore, as negative cytology can never completely
exclude the presence of a bladder tumor, cystoscopy is
warranted in all cases [1]. Cytology may be of use in the
identification of patients that warrant intense investigation.
3. Radiological Evaluation of Hematuria
The primary role of imaging is to identify those patients
with a malignant cause of haematuria. Currently no imaging
modality is sufficiently sensitive for the detection of urothelial
carcinoma of the bladder and cystoscopic evaluation of the
lower urinary tract is essential in the thorough evaluation
of haematuria [14]. The choice of modality to image the
upper urinary tract will depend on individual patient factors
such as age, the presence of risk factors for malignancy,
renal function, a history of calculus disease and pregnancy,
and other factors, such as local policy and practice, cost
effectiveness, and availability of resources.
There is no universal agreement about the optimal
imaging work up of haematuria. Several protocols for the
investigation of haematuria have been developed but they
vary considerably and a lack of robust data from randomized
control trials makes it difficult to formulate evidence-based
guidelines [1, 12].
First-line investigations often include conventional radio-
graphy, renal ultrasound, and/or IVU in combination with
cystoscopy. Second-line investigations include MDCTU and
MRU, often only carried out if the first-line tests reveal an
abnormality [14].
Previous protocols that incorporated a combination of
renal ultrasound and IVU are now being superseded by
MDCTU, which represents a one-stop diagnostic technique
for the patient [20].MDCTU is themost sensitive and specific
test for the diagnosis of urinary tract calculi and for detecting
and characterizing renal masses [21]. MDCTU has been
shown to be more sensitive, specific, and accurate than IVU
in the diagnosis of upper urinary tract urothelial carcinoma
in patients with haematuria [22]. Furthermore, MDCTU
has the advantage of imaging the periureteric tissues and
retroperitoneum while excretory urography only images the
ureteric lumen and cannot adequately depict any extrinsic
abnormalities [23]. The superior diagnostic performance of
MDCTU over IVU in the detection of malignancy, combined
with recent advances in dose reduction and a wider avail-
ability of the technique, has led many authors to recommend
MDCTU as a first-line modality to image the upper urinary
tract in patients with haematuria.
The role ofMRU is also increasing, although it is currently
inferior toMDCTU in the detection of urothelial malignancy
[24].
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4. Conventional Radiography
The kidneys, ureters, and bladder (KUB) radiograph is
currently of little value in the investigation of patients with
haematuria [25].
Traditionally, the main role of radiography has been
in the detection of calculus disease despite only moderate
sensitivities in the range of 45 to 60% [26]. KUB cannot
visualize radiolucent calculi (10–20%of calculi) and overlying
bowel gas, faecoliths, and phleboliths canmake interpretation
difficult [25].
CT KUB or “stone protocol CT” is now the first-line
imaging investigation in the diagnosis of calculus diseasewith
a reported sensitivity of 96% to 100% and a specificity of 94%
to 100% [27, 28]. The major limitation to the initial universal
acceptance of CT KUB as a first-line test was the significantly
higher radiation dose incurred by the patient. However, low-
dose and ultralow-dose CT protocols have reduced radia-
tion exposure by approximately 50% and 95%, respectively,
comparedwith standard-dose CT, with comparable detection
rates of calculi [29, 30]. Kluner et al. reported ultralow-
dose CT with a high diagnostic accuracy obtained at doses
equivalent to that of a conventional radiograph (0.5mSv in
men and 0.7mSv in women) [30]. Furthermore, CT can
assess for the presence of hydronephrosis or identify alter-
native causes of the patient’s haematuria and extraurinary
pathology. The reported incidence of extraurinary pathology
with CT performed for suspected calculus disease is 12% [31].
KUB has no role in the detection of renal and urothelial
carcinoma due to its limited sensitivity. Evidence of a malig-
nancy such as calcification within a urothelial carcinoma
may occasionally be provided [32]. Approximately 15% of
renal cell carcinomas contain calcifications that are visible
on conventional radiographs [33]. In general, radiography
should be avoided, especially in high-risk patients, as further
imaging will almost always be required [2].
5. Intravenous Urography
Since it was first performed by Osborne et al. in 1923
[34], intravenous urography (IVU) has been the traditional
“gold standard” in the evaluation of the upper urinary tract
[35]. Its main strength is that it images the entire upper
urinary tract with a high degree of spatial resolution allowing
detection of even small urothelial tumors. It has a reported
sensitivity of 60.5% and specificity of 90.9% for the detection
of urological abnormalities in patients with haematuria [36].
It also provides structural information as well as limited
functional data, is widely available, and is often the most
cost-efficient test in many centers. Its disadvantages include
a lengthy acquisition time, the radiation dose involved, and a
risk of contrast reaction [3]. Mean effective radiation doses in
the range of 3.6mSV to 9.6mSv have been reported with IVU
[37, 38]. In contrast, a three-phase CTU has a mean effective
dose of 14.8mSv plus orminus 9mSv, corresponding to a dose
1.5 times higher than IVU [38].
IVU can also depict renal masses although it is not
possible to distinguish a cyst from a solid mass and many
lesions can go undetected (Figures 1 and 2) [39]. It has a
Figure 1: Intravenous urogram (bladder image obtained 15 minutes
following contrast administration). There is an infiltrative mass
lesion involving the bladder wall on the right. This was confirmed
to be a urothelial cell carcinoma following biopsy at cystoscopy.
Figure 2: Intravenous urogram demonstrates a filling defect in the
lower pole calyx of the left kidney, a histologically-proven urothelial
cell carcinoma.
limited sensitivity for detecting renal masses less than 3 cm
in size (reported sensitivities of 21% for masses less than
2 cm and 52% for masses 2 to 3 cm in size) [40] and, even
when a mass is identified, further imaging, usually with CT,
is required to characterize the lesion.
Current evidence casts doubt on the role of IVU as the
“gold standard” for urothelial imaging and in recent years
the dominant role of IVU has been surpassed by MDCTU
[41]. MDCTU has been shown to be more accurate in the
diagnosis of upper urinary tract urothelial carcinoma with
a sensitivity of 96% and a specificity of 100% compared to
IVU with a sensitivity of 75% and a specificity of 86% [22].
A filling defect in the renal pelvis or ureter on an IVU
may be due to a neoplasm, calculus, blood clot, or possibly
a vascular impression, thus limiting accurate interpretation
without additional imaging [42]. CT has the advantage of
imaging the urinary tract and retroperitoneum concurrently,
thus leading to a higher diagnostic accuracy.
In the investigation of suspected urolithiasis, CT KUB
is now a well-accepted alternative to IVU with superior
calculus detection rates reported in several studies [43]. A
potential limitation of CT is its inability to provide functional
data that would otherwise be derived from the excretory
times during an IVU. However, some authors have suggested
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that secondary measures of obstruction such as hydroureter,
hydronephrosis, and perinephric fat stranding are a reliable
indicator of the degree of obstruction within a system and
comparable to delayed excretion on an IVU [44].
As with any imagingmodality, the protocol should ideally
be tailored to answer a specific clinical question. A standard
IVU protocol includes a preliminary KUB radiograph prior
to intravenous contrast administration which is followed by
a nephrotomogram or nephrographic images collimated to
the kidneys (1 to 3 minutes after contrast injection), a KUB
radiograph at 5 minutes after injection, a pyelographic image
at 10 minutes with abdominal compression applied after the
5-minute film and ureter-bladder images after compression
is released, and bladder images. Additional films such as
oblique images and additional tomograms may be obtained
at the discretion of the reporting radiologist [42].
The preliminary KUB is to identify renal and ureteric cal-
culi thatmay not be visible following contrast administration.
Multiple patterns of abnormality on IVU have been
described with urethelial carcinoma. These include smooth
or irregular ureteric filling defects seen in 35% of cases, filling
defects within dilated calices secondary to partial or complete
obstruction in 26%, or caliceal amputation in 19% of cases.
Mass lesions typically present with increased parenchy-
mal thickness with associated underlying calyceal distortion
[42].
6. Ultrasound
The primary advantage of ultrasound is the avoidance of
exposure to ionizing radiation. Thus, it is especially useful in
radiation-sensitive populations such as pregnant women and
pediatric patients. It is also a widely available and inexpensive
imaging modality and does not involve the administration of
intravenous contrast.
The sensitivity of ultrasound is variable depending on the
skill and experience of the operator and on the body habitus
of the patient.
Ultrasound is superior to IVU for the detection of renal
masses with reported sensitivities of 67% and 79% for IVU
and ultrasound, respectively [45, 46]. However, ultrasound
has a limited sensitivity for the detection of small renalmasses
and is inferior to CT (Figure 3). Jamis-Dow et al. reported
that for masses <1 cm, ultrasound detected 20% and CT
detected 76%and, formasses<2 cm, ultrasounddetected 70%
and CT detected 95%. For masses >3 cm, the results were
comparable [47]. Ultrasound may be more useful for lesion
characterization rather than detection as it can accurately
distinguish cystic from solid masses [11]. It is excellent
for defining the internal architecture of a renal mass and
determining the Bosniak grade, which guides management
and prognosis [48]. Ultrasound has been reported to be the
most cost effective method for the assessment of renal masses
detected at IVU as over 80% of these masses are found to be
simple cysts [49].
The major disadvantage of ultrasound is its limited
ability to thoroughly evaluate the urothelium for malignancy.
Detection of renal pelvis carcinoma is moderate (82%) but
Figure 3: Renal ultrasound demonstrates an exophytic hypoechoic
solid mass arising from the lower pole of the kidney consistent with
a renal cell carcinoma.
Figure 4: Retrograde pyelogram. There is an irregular infiltrative
mass involving the renal pelvis and proximal ureter. This was a
histologically proven urothelial cell carcinoma.
sensitivities as low as 12%have been reported for the detection
of urothelial carcinoma of the ureter [50]. Ultrasound can
often identify secondary signs of ureteric tumors such as
hydronephrosis and hydroureter.
Many protocols for the evaluation of haematuria have
used a combination of ultrasound and IVU with success for
a comprehensive assessment of the upper urinary tract [51].
Recent guidelines from the European Society of Urogenital
Radiology state that ultrasound may be used alone in low-
risk patients to image the upper urinary tract but in high-risk
patients CT urography is warranted [52].
Ultrasound is also onlymoderately sensitive for the detec-
tion of renal calculi (67 to 77% sensitive) [53]. Typically, renal
cell carcinomas (RCC) are solid with 50% being hyperechoic
to renal parenchyma and 40% being isoechoic. Urothelial
carcinomas tend to be slightly hyperechoic relative to the
surrounding renal parenchyma, occurmore centrally, and are
often associated with focal hydronephrosis [54].
7. Retrograde Pyelography
Retrograde pyelography can image the renal pelvis and
ureters with a high degree of spatial resolution (Figure 4).
However, in recent years, CTU has been found to have
a greater diagnostic accuracy than retrograde pyelography
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Figure 5: CT urogram (coronal urographic phase image) demon-
strates a large polypoid mass arising from the bladder wall. This
was confirmed to be a urothelial cell carcinoma following biopsy at
cystoscopy.
for the detection of urothelial lesions [23, 55]. The high
contrast resolution of CTU offers excellent pelvicaliceal and
ureter visualization as well as visualization of the periureteral
tissues and retroperitoneum [41]. Retrograde pyelography
may still be employed as a second-line investigation to further
characterize filling defects detected on other modalities, or in
patientswith renal failure or cases of contrastmediumallergy.
8. Computed Tomography
The role of CT in imaging the urinary tract has expanded
in recent years, particularly with the advent of multidetector
(MDCT) scanners and CT urography (CTU). Contrast-
enhanced CT is firmly established as the overall most sen-
sitive modality for determining the cause of haematuria [41].
It is the gold standard in the detection of renal parenchymal
masses, calculi, upper tract urothelial tumors, and extrinsic
lesions [14].
In patients presenting with acute renal colic, CTKUBwill
identify ureteric and bladder calculi with a sensitivity of 96%
to 100% and a specificity of 94% to 100% [27, 28]. Multiphase
contrast-enhanced CT is also more sensitive than IVU and
ultrasound in detecting renal masses with a sensitivity of 94%
compared to 67% for IVU and 79% for ultrasound [40]. It also
provides excellent lesion characterization as well as imaging
the adjacent retroperitoneum and providing information
about the local and distant spread of malignancies (Figures
5, 6, and 7) [56]. CTU has a greater sensitivity in diagnosing
upper tract urothelial malignancy than IVU, with a reported
sensitivity of 95% compared to 75% with IVU [22].
When CT is chosen to image the upper urinary tract,
the imaging protocol should be adapted to the patient and
the diagnostic goals, such as the exclusion of urolithiasis or
malignancy. CTU aims to generate multiphase thin-section
images through the kidneys, ureters, and bladder that allow
for the detection of the most common urological causes of
hematuria, including calculi, renal masses, and urothelial
tumors [57].
An unenhanced scan is initially performed from the
upper poles of the kidneys to the lower edge of the symphysis
pubis using 3mm to 5mm thick sections in the prone
Figure 6: CT of kidneys (coronal nephrographic phase image)
demonstrates an enhancing mass lesion arising from the lower pole
of the left kidney consistent with a histologically confirmed renal cell
carcinoma.
Figure 7: CT urogram (coronal urographic phase image) demon-
strates a filling defect in the upper moiety of a duplex right kidney.
This was histologically confirmed to be urothelial cell carcinoma
following ureteroscopy and biopsy.
position. High attenuation oral contrast should be avoided,
as dense contrast can make detection of ureteric calculi more
difficult [58].
This is followed by nephrographic phase (90–100 seconds
after contrast administration) imaging of the kidneys, and
excretory phase imaging (8–15 minutes after contrast admin-
istration) of the entire urinary tract. Additional urograms
including prone and oblique projection images and further
delayed imagesmay be useful in imaging obstructing ureteral
lesions as well as bladder lesions [59].
The unenhanced series will detect urinary tract calculi
with a high degree of diagnostic accuracy.The prone position
is used to discriminate free intravesical calculi from those
impacted at the vesicoureteric junction. The unenhanced
series is also used to determine if a cyst is hyperdense or
if any solid lesions demonstrate enhancement on subse-
quent phases. The nephrographic phase is the optimal phase
for the detection of renal parenchymal masses [41]. Two-
dimensional and three-dimensional intravenous urography-
like images can be obtained by reformatting excretory phase
images in the coronal or sagittal planes using volume render-
ing or maximum intensity projection techniques [41].
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Traditionally, CTU is performed as a three-phase, single-
bolus examination. However, many now advocate the use of a
two-phase, split bolus technique, as it can significantly reduce
the radiation dose incurred by the patient while maintaining
diagnostic accuracy [60].
The use of dual energy CT urography has also been
described recently with centers performing single-phase
dual energy CT with synchronous nephrographic-excretory
phases and reporting dose savings of up to 45% compared to
standard dual-phase protocols [61].
Dose savings have also been reported with the use
of material decomposition images generated from spectral
CT urography allowing omission of the unenhanced scan
without compromising on the detection of calculi [62].
Several authors have reported poor opacification of distal
ureteric segments during CTU. Many different adjuncts have
been added to CTU protocols in an attempt to improve
ureteric opacification and distension. Several studies have
examined the role of oral or intravenous hydration of the
patient with normal saline prior to the examination, but this
technique has not been widely adapted with most concurring
that it does not improve opacification of the ureters [63].
Furosemide administration in low doses has been shown
to be an effective and convenient technique for improv-
ing ureteric opacification. A recent comparison of intra-
venous furosemide and saline infusion prior to CTU found
furosemide to be superior with complete ureteric opacifica-
tion reported in 93% of cases [64].
Intravenous furosemide has also been used to detect and
characterize renal calculi in mixed nephrographic excretory
phase dual energy CT [65].
The primary deterrent limiting universal acceptance of
CTU as the first-line investigation in patients with haema-
turia is the radiation dose which incurred. A mean effective
dose of 14.8mSv plus or minus 9mSv has been reported for a
standard three-phase CTU compared to IVU with a reported
dose range of 3.6mSv to 9.6mSv [38].
The use of two-phase studies, split-bolus techniques, or
even one-phase studies in low risk patients can all reduce
radiation dose [14]. Single-phase dual-energy CT has been
shown to represent an accurate “all-in-one” approach to the
investigation of haematuria with a radiation dose reduction
of 45% compared with a standard dual-phase protocol [61].
This technique involves the reconstruction of virtual unen-
hanced images from enhanced images and allows for fast and
accurate characterization of renal masses in a single-phase
acquisition [66].
Other disadvantages of CT include its unavailability in
some centers, the risk of allergic reaction and nephrotoxicity
with contrast administration, and its cost compared to IVU
and ultrasound [12].
Renal cell carcinoma demonstrates early enhancement
and washout following contrast material administration.
Renal cell carcinoma, being hypervascular, tends to enhance
more than urothelial carcinoma, although it is often difficult
to differentiate the two tumors [20]. Enhancement of greater
than 10HU compared to unenhanced images suggests that
a mass is solid while enhancement of greater than 20HU
strongly suggests that a mass is malignant [67].
Renal pelvis urothelial carcinoma may be seen as sessile
filling defect that expands centrifugally compressing and dis-
placing renal sinus fat or present as a pelvicaliceal irregularity,
focal or diffuse mural thickening, or as an oncocalyx [54].
Ureteric lesions typically present with eccentric or circumfer-
ential wall thickening, luminal narrowing, or hydronephrosis
to the level of the lesion [54].
CTU clearly outperforms conventional radiography,
ultrasound, and IVU in the detection of renal parenchymal
masses and urinary tract calculi. However, the relatively high
radiation dose involved has prevented CTU from becoming
the first-line test in all patients with haematuria.
9. Magnetic Resonance Urography
MRU is an evolving technologywith the potential to provide a
noninvasive “one-stop shop” comprehensive evaluation of the
upper urinary tract and surrounding structures without the
use of ionizing radiation. MR imaging offers inherently high
soft-tissue contrast, is independent of excretory function, and
allows multiplanar imaging, without the need for ionizing
radiation.
MRI has been shown to be comparable to CT in the detec-
tion of renal masses (Figure 9) [68]. As with CT, MRI can
demonstrate tumor involvement of the renal parenchyma and
perinephric tissues as well as detecting distant metastases.
A significant short falling of MRI is its relative insensi-
tivity for the detection of urinary tract calculi. In one series
in which MRU was compared with noncontrast CT, MRU
was inferior in the detection of calculi but detected a greater
number of secondary signs of obstruction. It may be of
value in situations in which exposure to ionizing radiation
is undesirable [69, 70]. The sensitivity of MRU in detecting
urothelial lesions also remains unclear but at present is not
believed to be equivalent to IVU or CTU [59]. It also has only
a moderate accuracy for the detection of bladder carcinoma
[71]. Other disadvantages of MRI include its relatively long
imaging times, limited availability, cost, sensitivity tomotion,
susceptibility to artifacts, and lower spatial resolution com-
pared with CT and conventional radiography.
MRU has a specific role in the evaluation of painful
hydronephrosis in pregnancy. Not only can it image the
urinary tract without the need for ionizing radiation or
contrast administration, but it can also reliably distinguish
between physiological and calculus obstruction (Figure 8)
[72].
MR urographic techniques used to display the urinary
tract include static-fluid MRU (also known as T2-weighted
MR urography) and excretory MRU (also known as T1-
weighted MR urography) [70].
Static-fluid MRU techniques closely resemble those used
for T2-weighted MR cholangiopancreatography and use
heavily T2-weighted sequences to generate IVU-like images
of the urinary tract.
Static-fluid MRU does not require the excretion of con-
trast material and is therefore useful for demonstrating the
collecting system of an obstructed, poorly excreting kidney.
Excretory MR urography is roughly analogous to IVU and
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Figure 8: T2-weighted MR urography demonstrates a mass at the
upper pole of the left kidney directly invading the renal pelvis.
Figure 9: Coronal T2-weighted MRI of kidneys shows a large
heterogeneous low T2 signal mass centered in the upper pole of the
left kidney.
CTU and uses gadolinium-enhanced T1-weighted sequences
to depict the urinary tract [70].
Urinary tract calculi appear as filling defects on both
static-fluid and excretory MR urography when surrounded
by urine or contrast material.
At MR urography, ureteric tumors typically appear as an
irregular mass which demonstrates contrast enhancement,
distinguishing them from calculi [54].
Renal cell carcinoma has variable signal characteris-
tics on T1- and T2-weighted sequences and demonstrates
early enhancement following contrast administration. Renal
pelvis urothelial tumors are normally isointense to renal
parenchyma on T1- and T2-weighted images and are best
visualized as low-signal filling defects on heavily T2-
weighted or excretory contrast-enhancedT1-weighted images
[73].
MRUcurrently serves as an alternative imaging technique
to IVU and CT in radiation-sensitive patients such as preg-
nant women and children and in patients with contraindi-
cations to iodinated contrast media. It has not been widely
adopted into clinical practice or thoroughly evaluated for
effectiveness and is not currently recommended as a first-line
examination.
10. Conclusion
Many authorities cite a lack of sufficient evidence to drawfirm
conclusions and formulate evidence-based guidelines on the
best imaging modality to evaluate haematuria.
Conventional radiography has no role in the investigation
of haematuria. Ultrasound remains an important diagnostic
tool for the evaluation of haematuria in radiation-sensitive
populations and low-risk patients. Retrograde pyelography
remains useful for characterizing filling defects detected on
other modalities, such as IVU and CTU. MRU is emerging
as a potentially noninvasive comprehensive imaging test for
evaluating the upper urinary tract without the use of ionizing
radiation and thus is particularly useful in children and
pregnant women.
It is widely accepted that CTU outperforms conventional
radiography, ultrasound, and IVU in the detection of renal
parenchymal masses and urinary tract calculi.
The main limitation of CTU is the associated radiation
exposure and thiswas initially amajor factorwhich prevented
it from becoming universally accepted as the first-line inves-
tigation in patients with haematuria. Recent guidelines from
the European Society of Urogenital Radiology have suggested
that CTU may be used in high-risk patients in whom the
risk of malignancy outweighs the risk of radiation exposure
[52]. CT serves as a “one-stop shop” imaging test for patients,
thereby saving time and hospital visits and leading to earlier
diagnosis. Examination protocols should be tailored to the
patient while all the while optimizing radiation dose.
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